AI for Diabetes Management: DiaSmart AI Pitch Deck

DiaSmart AI

Revolutionizing Diabetes Mellitus Management with Artificial Intelligence

The Problem: Epidemiology & Scale

Diabetes Mellitus is a rapidly expanding global crisis. In the US alone, over 38 million people are affected, with a significant portion remaining undiagnosed. The burden is compounded by nearly 98 million adults living with prediabetes, creating a massive pipeline for future chronic care needs.

Etiology & Pathophysiology

Understanding the root cause is critical for effective management. • Type 1 Diabetes: Autoimmune destruction of pancreatic beta-cells leading to absolute insulin deficiency. • Type 2 Diabetes (Primary Focus): Characterized by peripheral insulin resistance paired with progressive beta-cell dysfunction. Driven by genetics, obesity, and physical inactivity.

Clinical Manifestations & Diagnosis

Common Symptoms: Polyuria (frequent urination), Polydipsia (excessive thirst), Weight Loss, and chronic Fatigue.

Acute Complications: Diabetic Ketoacidosis (Type 1) and Hyperosmolar Hyperglycemic State (Type 2).

Diagnostic Criteria: HbA1c ≥ 6.5% indicating long-term glucose exposure.

Fasting Measure: Fasting Plasma Glucose ≥ 126 mg/dL confirms diagnosis.

The Solution: DiaSmart AI Platform

We bridge the gap between diagnosis and daily management. Our platform integrates continuous glucose monitoring (CGM) data with an AI pathophysiology simulator to predict complications before they happen. Features include a real-time symptom checker, automated diet calibration, and medication adherence alerts.

Comprehensive Management Strategy

Non-Pharmacological: Medical Nutrition Therapy (MNT), weight management, and physical activity are the first line of defense.

Pharmacological (Oral): Metformin remains the preferred initial pharmacologic agent for T2DM.

Pharmacological (Injectable): GLP-1 receptor agonists & SGLT2 inhibitors for cardiorenal protection.

Therapeutic Goal: To prevent acute complications and reduce the risk of long-term microvascular events.

Market Opportunity

The economic burden of diabetes is staggering. While the Total Addressable Market represents the $622B projected US cost burden by 2030, our Serviceable Obtainable Market targets the high-risk segment through digital therapeutics, representing a $500M initial revenue opportunity.

Business Model & Monetization

1. Freemium B2C App: Basic tracking is free; AI-driven predictive insights and meal planning are $9.99/mo. 2. B2B Enterprise Partnerships: Licensing platform to payers and self-insured employers for population health management. 3. Data Insights: Aggregated, anonymized data licensing for pharmaceutical research and clinical trials.

Competitive Landscape

vs. Dexcom/Abbott: They provide hardware (CGMs) but lack holistic lifestyle integration. We partner, not compete, by utilizing their data layers.

vs. Noom/Omada: General behavioral coaching lacks the specific medical etiology modeling for diabetes complications.

The DiaSmart Edge: We are the only solution combining clinical pathophysiology simulation with behavioral modification.

Financial Projections (5-Year)

Driven by B2B adoption and international expansion in Year 3. We project aggressive growth to $250M revenue by Year 5, capitalizing on the rising global prevalence of diabetes and the shift toward digital health reimbursement.